MetaVia to Present Innovative DA-1241 Research at ADA's 85th Scientific Sessions

MetaVia's Groundbreaking Presentation at ADA 85th Scientific Sessions

MetaVia Inc., a promising player in the clinical-stage biotechnology sphere, has announced a pivotal development that could reshape treatment landscapes for cardiometabolic diseases. On June 4, 2025, the company disclosed that an abstract highlighting significant pre-clinical data on its promising drug, DA-1241, has been accepted for poster presentation at the esteemed American Diabetes Association's 85th Scientific Sessions. This scientific gathering is a pivotal moment for the medical community, and MetaVia's findings will be showcased from June 20 to June 23, 2025, at the McCormick Place Convention Center located in Chicago, Illinois.

The presentation will focus on the title "Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH." This research, presented by Yuna Chae, the Lead Research Scientist at Dong-A ST Research Center, aims to shed light on how DA-1241 works synergistically with Efruxifermin in impacting metabolic functions and liver health, particularly relevant for patients grappling with Metabolic Dysfunction-Associated Steatohepatitis (MASH).

During the session marked as 22-C Integrated Physiology—Liver, Yuna Chae will present findings between 12:30 PM and 1:30 PM CT on June 22, 2025. Attendees can look forward to pivotal insights on how DA-1241 acts as a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with potential in both standalone and combination therapies. The implications for treating both MASH and type 2 diabetes are vast, highlighting DA-1241's potential to facilitate the release of critical gut peptides such as GLP-1, GIP, and PYY.

Several pre-clinical studies have demonstrated encouraging results, with DA-1241 showing promise in improving glucose metabolism, lipid profile, and even alleviating liver inflammation. Specifically, the drug has displayed notable efficacy in reducing hepatic steatosis, fibrosis, and inflammation in various pre-clinical models of T2D and MASH.

Furthermore, the drug's performance in early Phase trials (1a, 1b, and 2a) demonstrates an excellent safety profile, presenting a vital opportunity for advancing the management of these complex metabolic disorders. These studies have evidenced DA-1241’s ability to enhance hepatic function while lowering glucose levels, which are crucial aspects of treatment for conditions tied to metabolic dysregulation.

MetaVia is also progressing with other therapeutic candidates, such as DA-1726, which targets obesity through a dual agonist mechanism affecting GLP1R and GCGR. In recent studies, DA-1726 has position itself as a leading option for achieving significant weight loss and metabolic control compared to traditional treatments.

In summary, MetaVia's upcoming presentation on DA-1241 at the ADA’s 85th Scientific Sessions carries the potential to shift paradigms in cardiometabolic disease treatment. With its innovative approach to activating the GPR119 receptor and emphasizing the importance of gut-derived peptides, DA-1241 could stand as a cornerstone in future therapeutic strategies. Following the presentation, the poster featuring these insights will be accessible on MetaVia's website and published online in the journal Diabetes, offering further clarity and information to the scientific community at large.

For ongoing updates and additional information about their research initiatives, interested parties can visit MetaVia’s official website.